AstraZeneca Annual Report and Form 20-F Information 2015最佳赛事竞猜平台


lol投注平台



2015 was an exceptional year for AstraZeneca, as we made significant progress in meeting both our near- and longer-term strategic goals.

Pascal Soriot, Chief Executive Officer




lol投注平台


All growth rates at CER.  



lol投注平台

lol投注平台

AstraZeneca is a global, science-led biopharmaceutical business with an on-market 文件夹 in our chosen therapy areas.




lol投注平台

We have distinctive R&D capabilities in small molecules, biologics, immunotherapies, protein engineering and devices.

最佳赛事竞猜平台


lol投注平台

We have a strong global commercial presence, with strength in Emerging Markets.


lol投注平台

Our talented employees are committed to achieveing our Purpose in a sustainable way.



lol投注平台


lol投注平台


lol投注平台


All employee numbers are approximate as at 31 December 2015.



lol投注平台

Increasing our proximity to bioscience clusters and co-locating around three strategic R&D centres.


lol投注平台

Gaithersburg, Maryland US
lol投注平台

Gothenburg, Sweden
lol投注平台




lol投注平台

Our disciplined capital allocation enables commitment to a progressive dividend.


Net cash shareholder distributions increased to $3,443 million
最佳赛事竞猜平台

最佳赛事竞猜平台

最佳赛事竞猜平台

lol投注平台

最佳赛事竞猜平台

The Board of Directors has sought to ensure that AstraZeneca's achievements in 2015 were underpinned by strong corporate governance.

Leif Johansson, Chairman